Cannabinoids has Antitumor Effects
Marijuana Weed Delivery Woodland Hills— One study with mice and rats suggested that cannabinoids may help keep certain types of tumors from growing. During this 2-year study, different amounts of THC were given by gavage to groups of mice and rats. The number of hepatic adenoma tumors and hepatocellular carcinoma (HCC) in the mice went down as the dose went up. The rats also had fewer benign tumors (polyps and adenomas) in their mammary glands, uteruses, pituitaries, testes, and pancreas. In another study, it was found that delta-9-THC, delta-8-THC, and cannabinol stopped the growth of Lewis lung adenocarcinoma cells both in the lab and in living animals. Cannabinoids have also been shown to stop the growth of other tumors.
Cannabinoids may have antitumor effects in a number of ways, such as by causing cancer cells to die, stopping them from growing, and stopping them from spreading. Two reviews explain how cannabinoids work at the molecular level as antitumor agents. Cannabinoids seem to kill tumor cells, but they don’t seem to hurt the cells that haven’t changed, and they may even protect them from dying. For example, these compounds have been shown to cause glioma cells in culture to commit suicide (apoptosis) and glioma tumors in mice and rats to shrink, while protecting normal glial cells of the astroglial and oligodendroglial lineages from suicide (apoptosis) caused by the CB1 receptor.
CBD has also been shown to protect against colon cancer in a mouse model of the disease. In this experiment, azoxymethane caused the mouse colon to get more precancerous and cancerous lesions. Animals given azoxymethane and CBD at the same time were less likely to get precancerous or cancerous lesions. In in vitro experiments with colorectal cancer cell lines, researchers found that CBD protected DNA from damage caused by oxidation, raised endocannabinoid levels, and slowed cell growth. In a later study, researchers found that selective CB1 receptor antagonists, but not CB2 receptor antagonists, could stop CBD from stopping cell growth. This suggests that CB1 receptors are involved.
In HCC, researchers looked at the effects of delta-9-THC and a man-made agonist of the CB2 receptor. Both agents decreased the number of HCC cells that could live in a lab dish, and HCC subcutaneous xenografts in naked mice showed antitumor effects. The studies showed that the CB2 receptor is what makes the anti-HCC effects happen. Similar to what was found in glioma cells, cannabinoids were found to cause cell death by stimulating an endoplasmic reticulum stress pathway that activates autophagy and promotes apoptosis. Other research has shown that CB1 and CB2 receptors may be possible targets in non-small cell lung carcinoma and breast cancer.
An in vitro study of the effect of CBD on programmed cell death in breast cancer cell lines found that CBD caused programmed cell death regardless of the CB1, CB2, or vanilloid receptors. CBD stopped both estrogen receptor–positive and estrogen receptor–negative breast cancer cell lines from living. It did this by causing apoptosis in a concentration-dependent way, but it had little effect on mammary cells that don’t turn into tumors. In preclinical models of breast cancer, other studies have also shown that cannabinoids (such as CBD and THC) kill cancer cells.
More is to researched, that is why it is better to be updated on the latest studies, together with Local Weed Delivery USA, let’s stay well-informed and educated.